Latest News

Study identifies potential approach to treat severe respiratory distress in patients with COVID-19



Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19. Researchers observed that the off-label use of the cancer drug acalabrutinib, a BTK inhibitor that is approved to treat several blood cancers, was associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients.

Source link

Related posts

BIOTRONIK Releases BIOMONITOR III Injectable Cardiac Monitor

Newsemia

Medical News Today: Ritalin vs. Adderall: What's the difference?

Newsemia

Wildfire Smoke Does This To Your Body So Beware

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World